All Companies

MRKCongressional Stock Trades

Merck & Co., Inc.

Pharmaceutical Preparations

Congressional stock trades in Merck & Co., Inc. (MRK) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

41

Politicians Trading

18

Last Traded

Aug 24, 2026

Trading History

PoliticianNotifiedTradedTypeAmountChange
Maria Elvira SalazarRSep 9, 2026Aug 19, 2026Buy$15,001 - $50,000-3.50%
Maria Elvira SalazarRSep 9, 2026Aug 19, 2026Buy$15,001 - $50,000-3.50%
Marjorie Taylor GreeneRAug 29, 2025Aug 28, 2025Buy$1,001 - $15,000+76.51%
Lisa C. McClainRAug 13, 2025Jun 24, 2025Buy$1,001 - $15,000+82.86%
Robert BresnahanRMay 8, 2025Apr 8, 2025Buy$15,001 - $50,000+86.03%
Marjorie Taylor GreeneRMay 6, 2025May 5, 2025Buy$1,001 - $15,000+77.29%
Bruce WestermanRApr 16, 2025Mar 3, 2025Buy$1,001 - $15,000+57.67%
Marjorie Taylor GreeneRApr 11, 2025Apr 9, 2025Buy$1,001 - $15,000+79.31%
Jefferson ShreveRMar 9, 2025Feb 24, 2025Buy$15,001 - $50,000+60.92%

Price History

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).